BS: Tsinghua University, Beijing, China, 1986.
MS: Cornell University, Ithaca, NY, 1988.
PhD: Cornell University, Ithaca, NY, 1991.
Postdoctoral Fellow: Cornell University, Ithaca, NY, 1995.
Using transgenic and gene targeted mouse models to study the physiological and pathological roles of Rho GTPases and their regulators in hematopoiesis, neurogenesis, lung cancer development and small intestinal stem cell regulations mechanism based, rational design of small molecule inhibitors targeting Rho GTPase signaling modules and pathologic functions in cancer and blood diseases; mouse model studies of mTor signaling function in hematopoietic stem cells and small intestinal stem cells.
Experimental Hematology and Cancer Biology, Cancer and Blood Diseases
Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition. Proceedings of the National Academy of Sciences of USA. 2021; 118:e2020102118.
Yap1-Scribble polarization is required for hematopoietic stem cell division and fate. Blood. 2020; 136:1824-1836.
Adaptive response to inflammation contributes to sustained myelopoiesis and confers a competitive advantage in myelodysplastic syndrome HSCs. Nature Immunology. 2020; 21:535-545.
ARHGEF12 regulates erythropoiesis and is involved in erythroid regeneration after chemotherapy in acute lymphoblastic leukemia patients. Haematologica: the hematology journal. 2020; 105:925-936.
Latexin regulation by HMGB2 is required for hematopoietic stem cell maintenance. Haematologica: the hematology journal. 2020; 105:573-584.
Rho GTPase-Activating Proteins in Cancer. The Rho GTPases in Cancer. : Springer Nature; Springer Nature; 2010.
Monogenic deficiency in murine intestinal Cdc42 leads to mucosal inflammation that induces crypt dysplasia. Genes and Diseases. 2024; 11:413-429.
Conserved and Unique Regulatory Mechanisms of RUNX1 in Hematopoietic Stem/Progenitor Cell Subpopulations in Both Normal Hematopoiesis and FPD/AML Development. Blood. 2023; 142:1314.
Kinase-independent role of mTOR and on-/off-target effects of an mTOR kinase inhibitor. Leukemia. 2023; 37:2073-2081.
Yi Zheng, PhD12/21/2020
Yi Zheng, PhD, Jose A. Cancelas Perez, MD, PhD7/1/2019